362 related articles for article (PubMed ID: 19495748)
1. Limited value of 18F-FDG PET/CT and S-100B tumour marker in the detection of liver metastases from uveal melanoma compared to liver metastases from cutaneous melanoma.
Strobel K; Bode B; Dummer R; Veit-Haibach P; Fischer DR; Imhof L; Goldinger S; Steinert HC; von Schulthess GK
Eur J Nucl Med Mol Imaging; 2009 Nov; 36(11):1774-82. PubMed ID: 19495748
[TBL] [Abstract][Full Text] [Related]
2. Value of tumour marker S-100B in melanoma patients: a comparison to 18F-FDG PET and clinical data.
Reinhardt MJ; Kensy J; Frohmann JP; Willkomm P; Reinhold U; Grünwald F; Biersack HJ; Bender H
Nuklearmedizin; 2002 Jun; 41(3):143-7. PubMed ID: 12109034
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy response assessment in stage IV melanoma patients-comparison of 18F-FDG-PET/CT, CT, brain MRI, and tumormarker S-100B.
Strobel K; Dummer R; Steinert HC; Conzett KB; Schad K; Lago MP; Soyka JD; Veit-Haibach P; Seifert B; Kalff V
Eur J Nucl Med Mol Imaging; 2008 Oct; 35(10):1786-95. PubMed ID: 18458901
[TBL] [Abstract][Full Text] [Related]
4. S-100B and FDG-PET/CT in therapy response assessment of melanoma patients.
Strobel K; Skalsky J; Steinert HC; Dummer R; Hany TF; Bhure U; Seifert B; Pérez Lago M; Joller-Jemelka H; Kalff V
Dermatology; 2007; 215(3):192-201. PubMed ID: 17823514
[TBL] [Abstract][Full Text] [Related]
5. Tumour assessment in advanced melanoma: value of FDG-PET/CT in patients with elevated serum S-100B.
Strobel K; Skalsky J; Kalff V; Baumann K; Seifert B; Joller-Jemelka H; Dummer R; Steinert HC
Eur J Nucl Med Mol Imaging; 2007 Sep; 34(9):1366-75. PubMed ID: 17390135
[TBL] [Abstract][Full Text] [Related]
6. The value of pre operative S-100B and SUV in clinically stage III melanoma patients undergoing therapeutic lymph node dissection.
Kruijff S; Bastiaannet E; Speijers MJ; Kobold AC; Brouwers AH; Hoekstra HJ
Eur J Surg Oncol; 2011 Mar; 37(3):225-32. PubMed ID: 21277729
[TBL] [Abstract][Full Text] [Related]
7. Use of S-100B to evaluate therapy effects during bevacizumab induction treatment in AJCC stage III melanoma.
Kruijff S; Bastiaannet E; Brouwers AH; Nagengast WB; Speijers MJ; Suurmeijer AJ; Hospers GA; Hoekstra HJ
Ann Surg Oncol; 2012 Feb; 19(2):620-6. PubMed ID: 21861214
[TBL] [Abstract][Full Text] [Related]
8. Utility of FDG PET/CT and brain MRI in melanoma patients with increased serum S-100B level during follow-up.
Aukema TS; Olmos RA; Korse CM; Kroon BB; Wouters MW; Vogel WV; Bonfrer JM; Nieweg OE
Ann Surg Oncol; 2010 Jun; 17(6):1657-61. PubMed ID: 20151211
[TBL] [Abstract][Full Text] [Related]
9. S-100B protein and melanoma inhibitory activity protein in uveal melanoma screening. A comparison with liver function tests.
Missotten GS; Korse CM; van Dehn C; Linders TC; Keunen JE; Jager MJ; Bonfrer JM
Tumour Biol; 2007; 28(2):63-9. PubMed ID: 17264538
[TBL] [Abstract][Full Text] [Related]
10. (18)F-fluorodeoxyglucose positron emission tomography/computed tomography and magnetic resonance imaging in patients with liver metastases from uveal melanoma: results from a pilot study.
Orcurto V; Denys A; Voelter V; Schalenbourg A; Schnyder P; Zografos L; Leyvraz S; Delaloye AB; Prior JO
Melanoma Res; 2012 Feb; 22(1):63-9. PubMed ID: 22027909
[TBL] [Abstract][Full Text] [Related]
11. S-100B concentrations predict disease-free survival in stage III melanoma patients.
Kruijff S; Bastiaannet E; Kobold AC; van Ginkel RJ; Suurmeijer AJ; Hoekstra HJ
Ann Surg Oncol; 2009 Dec; 16(12):3455-62. PubMed ID: 19636631
[TBL] [Abstract][Full Text] [Related]
12. Preoperative staging of liver metastases from uveal melanoma by magnetic resonance imaging (MRI) and fluorodeoxyglucose-positron emission tomography (FDG-PET).
Servois V; Mariani P; Malhaire C; Petras S; Piperno-Neumann S; Plancher C; Levy-Gabriel C; Lumbroso-le Rouic L; Desjardins L; Salmon RJ
Eur J Surg Oncol; 2010 Feb; 36(2):189-94. PubMed ID: 19775851
[TBL] [Abstract][Full Text] [Related]
13. S-100B as an extra selection tool for FDG PET/CT scanning in follow-up of AJCC stage III melanoma patients.
Deckers EA; Wevers KP; Muller Kobold AC; Damude S; Vrielink OM; van Ginkel RJ; Been LB; van Leeuwen BL; Hoekstra HJ; Kruijff S
J Surg Oncol; 2019 Nov; 120(6):1031-1037. PubMed ID: 31468535
[TBL] [Abstract][Full Text] [Related]
14. Detection of metastatic disease in patients with uveal melanoma using positron emission tomography.
Francken AB; Fulham MJ; Millward MJ; Thompson JF
Eur J Surg Oncol; 2006 Sep; 32(7):780-4. PubMed ID: 16765562
[TBL] [Abstract][Full Text] [Related]
15. The association between active tumor volume, total lesion glycolysis and levels of S-100B and LDH in stage IV melanoma patients.
Deckers EA; Kruijff S; Brouwers AH; van der Steen K; Hoekstra HJ; Thompson JF; Vállez García D; Wevers KP
Eur J Surg Oncol; 2020 Nov; 46(11):2147-2153. PubMed ID: 32819759
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of 18f-fluorodeoxyglucose positron emission tomography-computed tomography in predicting survival in patients with unresectable metastatic melanoma to the liver undergoing yttrium-90 radioembolization.
Piduru SM; Schuster DM; Barron BJ; Dhanasekaran R; Lawson DH; Kim HS
J Vasc Interv Radiol; 2012 Jul; 23(7):943-8. PubMed ID: 22609292
[TBL] [Abstract][Full Text] [Related]
17. Role of serum S100B and PET-CT in follow-up of patients with cutaneous melanoma.
Peric B; Zagar I; Novakovic S; Zgajnar J; Hocevar M
BMC Cancer; 2011 Aug; 11():328. PubMed ID: 21810220
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of serum S-100B in malignant melanoma.
Andrés R; Mayordomo JI; Zaballos P; Rodino J; Isla D; Escudero P; Elosegui L; Filipovich E; Saenz A; Polo E; Tres A
Tumori; 2004; 90(6):607-10. PubMed ID: 15762365
[TBL] [Abstract][Full Text] [Related]
19. Comparative study of YKL-40, S-100B and LDH as monitoring tools for Stage IV melanoma.
Egberts F; Kotthoff EM; Gerdes S; Egberts JH; Weichenthal M; Hauschild A
Eur J Cancer; 2012 Mar; 48(5):695-702. PubMed ID: 21917447
[TBL] [Abstract][Full Text] [Related]
20. Prospective monitoring of adjuvant treatment in high-risk melanoma patients: lactate dehydrogenase and protein S-100B as indicators of relapse.
Egberts F; Hitschler WN; Weichenthal M; Hauschild A
Melanoma Res; 2009 Feb; 19(1):31-5. PubMed ID: 19104452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
